The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable excitement within the medical community. This novel dual GIP and GLP-1 target medication seems to offer significant improvements in fat reduction compared to previous therapies. Early clinical data have shown significant reductions in body fat percentage, potential